phrykt

Roivant Sciences (ROIV) revenue: $8.3M

Roivant Sciences reported $8.3M of revenue for the year ended Mar 31, 2026, down 71.6% from $29.1M a year earlier.

From Roivant Sciences's filings with the SEC · Read the filing · ROIV stock page

Roivant Sciences revenue by year

$55.3M2021$31.5M2022$32.7M2023$29.1M2024$8.3M2025

#3,253 of 3,622 US companies by revenue · See the full ranking

Year endedRevenueChange
Mar 31, 2026$8.3M-72%
Mar 31, 2025$29.1M-11%
Mar 31, 2024$32.7M+4%
Mar 31, 2023$31.5M-43%
Mar 31, 2022$55.3M–

Revenue of similar companies

Companies in the same industry as Roivant Sciences, by SEC industry code, with the closest revenue. Each name opens the same page for that company.

CompanyRevenue, latest yearYear ended
Zenas BioPharma$10MDec 31, 2025
Janux Therapeutics$10MDec 31, 2025
Precigen$9.7MDec 31, 2025
Roivant Sciences$8.3MMar 31, 2026
Xenon Pharmaceuticals$7.5MDec 31, 2025
Immunome$6.9MDec 31, 2025
InMed Pharmaceuticals$4.9MJun 30, 2025

Questions and answers

What is Roivant Sciences's revenue?

Roivant Sciences reported $8.3M of revenue for the year ended Mar 31, 2026, down 71.6% from $29.1M a year earlier.

Numbers as reported in Roivant Sciences's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology